Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06095583 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
A Phase 3 study of Limited-stage Small Cell Lung Cancer (LS-SCLC), sponsored by Shanghai Junshi Bioscience Co..
- Recruiting
- Registry status
- Phase 3
- Development phase
- 756
- Enrollment target
- 20
- Study locations
NCT06095583 is a Phase 3 study of Limited-stage Small Cell Lung Cancer (LS-SCLC) that is actively recruiting participants, run by Shanghai Junshi Bioscience Co.. The registered enrollment target is 756 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT06095583, a Phase 3 study of Limited-stage Small Cell Lung Cancer (LS-SCLC), is actively recruiting participants, sponsored by Shanghai Junshi Bioscience Co..
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 756 participants
- Enrollment target
- 20
- Study locations
Study Summary
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy. Tifcemalimab is a monoclonal antibody against B and T lymphocyte attenuator (BTLA). Toripalimab is a monoclonal antibody against programmed death protein-1 (PD-1). Neither drug is approved for treatment of This combination regimen is investigational in limited stage-small cell lung cancer in any country.
Conditions Studied
Interventions
- DRUG Tifcemalimab injection
- DRUG toripalimab injection
- DRUG Placebo for Tifcemalimab
- DRUG Placebo for toripalimab
Study Locations (20)
California
- SCRI Nashville - Davis
- Zangmeister Cancer Center (Columbus, OH) - Los Angeles
- Los Angeles Hematology Oncology - Los Angeles
- University of Southern California Norris Comprehensive Cancer - Los Angeles
Florida
- Florida Cancer Specialists Pan Handle - Fort Myers
- Florida Cancer Specialists South - Fort Myers
- USA029 University of Miami Sylvester Comprehensive Cancer Center 1550 NW 10th Avenue 33173 Miami FL Ikpeazu Chukwuemeka N - Miami
- Mid-Florida Hematology Oncology - Orange City
Michigan
- Karmanos Cancer Center - Detroit
- Henry Ford Health System - Detroit
- Cancer and Hematology Centers of Western Michigan - Grand Rapids
Arizona
- Banner MD Anderson Cancer Center - Goodyear
- Banner University Medical Center - Tucson
Arkansas
- Genesis Cancer and Blood Institute (Hot Springs, AR) - Hot Springs
Georgia
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital - Marietta
Kentucky
- Norton Cancer Institute, Downtown, Multidisciplinary Clinic - Louisville
Maryland
- American Oncology Partners of Maryland, PA - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 756 participants |
| Start Date | 2023-11-15 |
| Est. Completion | 2029-07-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06095583
The ClinicalTrials.gov registry entry for NCT06095583 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 756 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shanghai Junshi Bioscience Co., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Limited-stage Small Cell Lung Cancer (LS-SCLC) appearing as the primary indexed condition, and to 4 interventions - of which Tifcemalimab injection is the first listed.
NCT06095583 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT06095583 about?
NCT06095583 is a clinical study titled "Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)". The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer with...
What is the current status of trial NCT06095583?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 756 participants. The study started on 2023-11-15. Estimated completion is 2029-07-31.
What conditions does trial NCT06095583 study?
This clinical trial studies the following conditions: Limited-stage Small Cell Lung Cancer (LS-SCLC).
What interventions are being tested in trial NCT06095583?
The interventions under investigation include: Tifcemalimab injection (DRUG), toripalimab injection (DRUG), Placebo for Tifcemalimab (DRUG), Placebo for toripalimab (DRUG).
Who is sponsoring clinical trial NCT06095583?
This trial is sponsored by Shanghai Junshi Bioscience Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06095583 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.